Stable pharmaceutical compositions of dihydroergotamine mesylate
The present invention relates to stable pharmaceutical compositions of dihydroergotamine mesylate or other pharmaceutically acceptable salts thereof and methods for preparing the compositions particularly for the treatment of migraine headaches. The invention further relates to stable injectable composition comprising dihydroergotamine or its pharmaceutically acceptable salts thereof, wherein the composition has a pH from about 5.0 to about 6.0. Further, the present invention relates to a method of treating migraine comprising providing a stable pharmaceutical composition for parenteral administration comprising dihydroergotamine mesylate, wherein the pH of the composition ranges from 5.0 to 6.0 and, wherein the composition comprises no greater than 3% of total impurities as determined by HPLC.
1. A method of treating migraine in a patient in need thereof, the method comprising providing a stable pharmaceutical composition comprising 1.0 mg/mL of dihydroergotamine mesylate;
wherein the pH of the composition ranges from 5.0 to 6.0;
wherein a level of 2′-epi-9,10-dihydro ergotamine is no greater than 2.0% w/w when stored at 25° C./60% relative humidity for 12 months as measured by HPLC, and
wherein said pharmaceutical composition is an injectable composition.
2. The method claim 1 , wherein the composition further comprises alcohol, glycerine, or a combination thereof.
3. The method of claim 2 , wherein the composition further comprises a pH adjusting agent.
4. The method of claim 3 , wherein the pH adjusting agent is methane sulfonic acid, sodium hydroxide or a combination thereof.
5. The method of claim 1 , wherein the pH of the injectable composition ranges from 5.2 to 5.5.
6. The method of claim 1 , wherein the composition comprises no greater than 2% of total impurities, as determined by HPLC.
7. The method of claim 1 , wherein the injectable composition comprises no greater than 2% 1.5% of 2′-epi-9,10-dihydro ergotamine.
8. The method of claim 1 , wherein the injectable composition comprises no greater than 1% of 2′-epi-9,10-dihydro ergotamine.
9. The method of claim 1 , wherein the injectable composition comprises no greater than 0.5% of 2′-epi-9,10-dihydro ergotamine.
10. The method of claim 1 , wherein said composition is stable for at least 3 months at 25±2° C. and 60±5% relative humidity.
11. The method of claim 1 , wherein said composition is stable for at least 24 months when stored under room temperature.